Novacell Technology Inc. has identified peptides acting as N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Legochem Biosciences Inc. has synthesized Toll-like receptor 7 (TLR7) and/or TLR8 agonists reported to be useful for the treatment of cancer, HIV infection, and hepatitis B virus infection.
Enanta Pharmaceuticals Inc. has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for diseases of the liver.
The U.S. FTC’s policing of Orange Book patent listings begs the question of when, and whether, the FDA will deliver on its commitment to provide more clarity on the types of device patents that can be listed as covering a “drug product.”
Gilgamesh Pharmaceuticals Inc. has described pyridine derivatives 5-HT2A receptor agonists reported to be useful for the treatment of depression, anxiety disorders, and substance abuse and dependency.
Vertex Pharmaceuticals Inc. has divulged heteroaryl compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Bristol Myers Squibb Co. has identified triazole N-linked carbamoyl cyclohexyl acids acting as lysophosphatidic acid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis, cancer, transplant rejection, osteoporosis, inflammatory disorders, neuropathic pain, atherosclerosis and chronic obstructive pulmonary disease, among others.
Vivace Therapeutics Inc. has synthesized transcriptional coactivator YAP1/TEAD and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer, polycystic kidney and hepatic fibrosis.
Synnovation Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities).
Itzhak Zachi Attia, an assistant professor of medicine and co-director of artificial intelligence (AI) in cardiology at Mayo Clinic, has filed for protection of an Al-based tool to detect cardiac amyloidosis (CA) from the analysis of voltage-time data captured from electrocardiograms (ECGs) acquired from a plurality of leads.
RSS
